Navigation Links
New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma

+ DOXIL to VELCADE monotherapy, the standard of care in patients with previously treated MM. Results were presented by Dr. Harousseau and showed:

    -- A survival advantage was observed for the VELCADE + DOXIL combination,

       after approximately 20 percent of events occurred (p<0.05, hazard

       ratio=1.406, 95 percent confidence interval [1.002; 1.972])

    -- Median time to progression (TTP) of 9.3 months for the combination, a

       43 percent, highly statistically significant reduction in risk of

       disease progression over the control arm (p<0.00001)

    -- A predictable safety profile consistent with the known toxicities of

       the two agents, including thrombocytopenia, neutropenia and anemia

The trial included 646 patients who had received at least one prior therapy. Patients were randomized in a one-to-one ratio, with 322 patients receiving VELCADE at 1.3 mg/m2 on days 1, 4, 8 and 11 of the 21-day cycle and 324 patients receiving the same dose and schedule of VELCADE with the addition of DOXIL at 30 mg/m2 given on day 4 of each cycle. Patients were treated for up to eight cycles. The primary endpoint of the study was TTP as defined by the interval between the date of randomization and the date of disease progression, including relapse after complete response or death due to disease progression. In both arms, 66 percent of patients had received more than two prior therapies before entering the trial. Responses were assessed by European Group for Blood and Marrow Transplantation (EBMT) criteria.

About Multiple Myeloma (MM)

Multiple myeloma is the second most common hematologic malignancy and although the disease is predominantly a cancer of the elderly (the average age of onset is 65 to 70 years of age), recent statistics indicate both increasing incidence and younger age of onset. In the U.S., more than 50,000 individuals have MM and 20,000 new cases are diagnosed each year. Worldwide there are approxi
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
5. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
8. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
9. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
10. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
11. Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies
Post Your Comments:
(Date:1/22/2015)... AMGN ) today announced that it will report its ... 27, 2015, after the close of the U.S. financial markets. The ... community at 2 p.m. PT. Participating in the call from Amgen ... officer, and other members of Amgen,s senior management team. ...
(Date:1/22/2015)... Institute for Clinical Research, Inc., a clinical research organization ... new textbook,  Translational Research Methods for Diabetes, Obesity and ... scientific publisher. The textbook is the first ... early phase clinical studies of new drugs for diabetes, ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/3h534b/infectious ) has announced ... by Product, Application, Technology, End User - Global Forecast ... The infectious disease diagnostics market is expected to ... by 2019 from $12,422.8 million in 2014. Increase in ...
Breaking Medicine Technology:Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... 6 Accumetrics, Inc., developer and marketer of the ... for measuring an individual,s response to multiple antiplatelet agents, ... financing that will raise $16.5 million in new capital. ... company into 2011, came from the company,s existing investors, ...
... Ltd. has started early Phase II clinical trial for RK-023, ... -- a new compound targeted as a treatment for androgenetic ... clinical trial in healthy male volunteers that began in 2008 ... clinical trial has been started for two purposes. One is ...
Cached Medicine Technology:Accumetrics Announces $16.5M in New Capital Financing 2Accumetrics Announces $16.5M in New Capital Financing 3R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023 2R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023 3
(Date:1/22/2015)... PA (PRWEB) January 22, 2015 Woodloch Pines, ... Mountains, has been selected by TripAdvisor as the number one ... the 6th best in the world for their annual Travelers’ ... online travel community . The website is home to millions ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... Plainsboro, NJ (PRWEB) January 22, 2015 ... advocate and keynote speaker at the upcoming 32nd ... by ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , ... breast would have gone undetected if she had not ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Four years since the ... – which coincided with the marriage of Avasa & Matthew Love ... ROAD, which is scheduled for release through White Swan Records on ... that there is a sacred path available to all of us ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... Honor of Huggies, 30th Anniversary, 30 Real Moms to be Featured ... ... of moms is,different from generations of the past. Strict definitions of ... their,roles on their terms. To celebrate its 30th anniversary, the Huggies ...
... today announced the launch of its superfast, low memory usage secure ... the PDF specs and is believed to be the smallest and ... ... 3, 2008 -- Drumlin Security (http://www.drumlinsecurity.co.uk) today announced the launch of ...
... Security as a,Service Provider (SaaS), announced today that ... Security Standard (DSS) version 1.2,released Oct. 1st by ... revised standard provides clarification and changes intended,to help ... is a Qualified Security Assessor Company (QSAC) and ...
... lives with at least one disability, CDC says , , THURSDAY, ... -- one in five people -- have some type of ... Prevention. , And a new CDC study finds that black, ... poor health at disproportionately higher rates than white or Asian ...
... The Association of,Clinical Research Organizations (ACRO) ... inaugural Clinical Outsourcing Leaders Summit with a ... research executives,November 13, 2008 in Washington, DC., ... interactive discussions,surrounding the impact of the presidential ...
... Weston Medical Publishing today,announced publication ... of Neurodegeneration,and Regeneration. (ISSN 1932-1481) This ... all aspects of neurodegeneration, neuroprotection and,neuroregeneration ... their relevance in treating neurodegenerative disorders ...
Cached Medicine News:Health News:Generation Huggies Celebrates 30 Years With 30 Moms 2Health News:Generation Huggies Celebrates 30 Years With 30 Moms 3Health News:SecureWorks Provides Solutions to Help with Payment Card Industry (PCI) Data Security Standard (DSS) Version 1.2 2Health News:SecureWorks Provides Solutions to Help with Payment Card Industry (PCI) Data Security Standard (DSS) Version 1.2 3Health News:SecureWorks Provides Solutions to Help with Payment Card Industry (PCI) Data Security Standard (DSS) Version 1.2 4Health News:SecureWorks Provides Solutions to Help with Payment Card Industry (PCI) Data Security Standard (DSS) Version 1.2 5Health News:SecureWorks Provides Solutions to Help with Payment Card Industry (PCI) Data Security Standard (DSS) Version 1.2 6Health News:Minorities With Disabilities Report Poorer Health 2Health News:Clinical Outsourcing Leaders Summit Set to Convene November 13 2Health News:New Journal to Explore Neurodegenerative, Neuroprotective and Euroregenerative Therapies! 2
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
... The Self-Cath Closed System is ... a method for safe, simple catheterization ... urinary tract infections. It includes ... The new EasyOff tear tab ...
... System is a latex-free unisex system ... simple catheterization designed to reduce the ... It includes a 100% latex-free Mentor ... tear tab makes it easy to ...
... family of 100% latex-free ... variety of options for ... catheter is made of ... and has smooth fire ...
Medicine Products: